{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:55:38Z","timestamp":1781978138704,"version":"3.54.5"},"reference-count":41,"publisher":"Impact Journals, LLC","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,16]]},"DOI":"10.18632\/oncotarget.10535","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T23:39:55Z","timestamp":1468280395000},"page":"53377-53391","source":"Crossref","is-referenced-by-count":37,"title":["Prexasertib, a Chk1\/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-\/T- cell progenitor acute lymphoblastic leukemia"],"prefix":"10.18632","volume":"7","author":[{"given":"Andrea Ghelli Luserna Di","family":"Ror\u00e0","sequence":"first","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Iacobucci","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Imbrogno","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Guadagnuolo","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Robustelli","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Parisi","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sartor","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Abbenante","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Paolini","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Seragnoli\u201d, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"1","first-page":"7","article-title":"New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia","volume":"9","author":"Moorman","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2","first-page":"6521","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome - positive acute lymphoblastic leukemia","volume":"118","author":"Propris","year":"2011","journal-title":"Therapy"},{"key":"3","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","article-title":"Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: Results of the Gruppo Italiano Malattie Ematologiche dell'Adu","volume":"109","author":"Ferrara","year":"2007","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.2015.124016","article-title":"Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia","volume":"100","author":"Biondi","year":"2015","journal-title":"Haematologica"},{"key":"5","first-page":"1097","article-title":"Development of cell-cycle checkpoint therapy for solid tumors","author":"Tamura","year":"2015","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"6","first-page":"139","article-title":"Cell-cycle dysregulation and anticancer therapy","author":"Pietenpol","year":"2003","journal-title":"Trends in Pharmacological Sciences"},{"key":"7","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3390\/biom5031912","article-title":"Targeting the Checkpoint to Kill Cancer Cells","volume":"5","author":"Macurek","year":"2015","journal-title":"Biomolecules"},{"key":"8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Bartek","year":"2004","journal-title":"Nature"},{"key":"9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-5793(01)02114-7","article-title":"Pathways governing G1\/S transition and their response to DNA damage","volume":"490","author":"Lukas","year":"2001","journal-title":"FEBS Lett"},{"key":"10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Roberts","year":"1999","journal-title":"Genes Dev"},{"key":"11","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00018-011-0875-3","article-title":"Eukaryotic DNA damage checkpoint activation in response to double-strand breaks","volume":"69","author":"Grenon","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"12","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","article-title":"ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1","volume":"21","author":"Piwnica-Worms","year":"2001","journal-title":"Mol Cell Biol"},{"key":"13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in cell biology and cancer therapy","volume":"134","author":"Hunter","year":"2014","journal-title":"Int J Cancer"},{"key":"14","first-page":"73","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","author":"Gillespie","year":"2010","journal-title":"Advances in Cancer Research"},{"key":"15","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","article-title":"Checkpoint kinase 1 in DNA damage response and cell cycle regulation","volume":"70","author":"Dong","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.coph.2005.04.009","article-title":"Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors","volume":"5","author":"Garrett","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tips.2011.02.014","article-title":"Anticancer therapy with checkpoint inhibitors: What, where and when?","volume":"32","author":"Collins","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","article-title":"CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy","volume":"142","author":"Bence Lin","year":"2014","journal-title":"Pharmacol Ther"},{"key":"19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clon.2014.01.009","article-title":"Selective Targeting of the G2\/M Cell Cycle Checkpoint to Improve the Therapeutic Index of Radiotherapy","volume":"26","author":"Harrington","year":"2014","journal-title":"Clin Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/mi.11.2.11","article-title":"CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle","volume":"11","author":"Grant","year":"2011","journal-title":"Mol Interv"},{"key":"21","doi-asserted-by":"publisher","first-page":"6553","DOI":"10.18632\/oncotarget.2720","article-title":"Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma","volume":"6","author":"Righi","year":"2015","journal-title":"Oncotarget"},{"key":"22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-015-0206-5","article-title":"In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia","volume":"8","author":"Ferrari","year":"2015","journal-title":"J Hematol Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1535-7163.MCT-08-0492","article-title":"AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies","volume":"7","author":"Caleb","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bcp.12139","article-title":"The cancer therapeutic potential of Chk1 inhibitors: How mechanistic studies impact on clinical trial design","volume":"76","author":"Eastman","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"25","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1021\/jm2007326","article-title":"Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing","volume":"54","author":"Proisy","year":"2011","journal-title":"J Med Chem"},{"key":"26","article-title":"LY2606368 causes replication catastrophe and anti-tumor effects through CHK1-dependent mechanisms","author":"Blosser","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"27","first-page":"94","article-title":"Treatment of acute lymphoblastic leukemia in adults","author":"Shami","year":"2012","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"28","article-title":"Tyrosine kinase inhibitors in Ph + acute lymphoblastic leukaemia : facts and perspectives","author":"Information","year":"2016","journal-title":"Ann Hematol"},{"key":"29","first-page":"459","article-title":"Clofarabine (2-chloro-2???-fluoro-2???-deoxyarabinosyladenine) - Biochemical aspects of anticancer activity","volume":"68","author":"Fabianowska-Majewska","year":"2011","journal-title":"Acta Pol Pharm - Drug Res"},{"key":"30","first-page":"631","article-title":"Clofarabine-based chemotherapy for relapsed\/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience","author":"Mart??nez-S??nchez","year":"2012","journal-title":"American Journal of Hematology"},{"key":"31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2174\/138955709788452586","article-title":"Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity","volume":"9","author":"Robak","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"32","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1535-7163.MCT-13-0404","article-title":"Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor","volume":"12","author":"Evangelista","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2014.10.009","article-title":"Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR\/ABL+ leukemia cells","volume":"39","author":"Lin","year":"2015","journal-title":"Leuk Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.4161\/cc.29214","article-title":"Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints","volume":"13","author":"Deacon","year":"2014","journal-title":"Cell Cycle"},{"key":"35","first-page":"1","article-title":"Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells","volume":"15","author":"Annunziata","year":"2015","journal-title":"BMC Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s10495-014-1010-3","article-title":"The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells","volume":"19","author":"Wang","year":"2014","journal-title":"Apoptosis"},{"key":"37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1476-4598-13-147","article-title":"Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells","volume":"13","author":"Massey","year":"2014","journal-title":"Mol Cancer"},{"key":"38","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/1538-7445.AM2011-4458","article-title":"J. Abstract 4458: Chk1 inhibition as a novel therapeutic strategy for treating triple negative breast and ovarian cancers","volume":"71","author":"Massey","year":"2011","journal-title":"Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1158\/1078-0432.CCR-09-1222","article-title":"Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine","volume":"15","author":"Russell","year":"2009","journal-title":"Clin Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"994","DOI":"10.4161\/cc.5.9.2722","article-title":"ATR-Chk1 axis protects BCR\/ABL leukemia cells from the lethal effect of DNA double-strand breaks","volume":"5","author":"Slupianek","year":"2006","journal-title":"Cell Cycle"},{"key":"41","article-title":"CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress","author":"Martins","year":"2014","journal-title":"Oncogene"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T23:41:19Z","timestamp":1656805279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":41,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2016,8,16]]}},"alternative-id":["10535","27438145"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10535","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]}}}